Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.

Nakamuta M, Fujino T, Yada R, Yasutake K, Yoshimoto T, Harada N, Yada M, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nishinakagawa T, Machida K, Matsunaga K, Nakashima M, Kotoh K, Enjoji M.

Int J Clin Pharmacol Ther. 2010 Jan;48(1):22-8.

PMID:
20040336
2.

Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.

Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N.

J Gastroenterol. 2006 Jul;41(7):686-92.

PMID:
16933007
3.

Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis.

Akbar SM, Furukawa S, Nakanishi S, Abe M, Horiike N, Onji M.

J Gastroenterol. 2005 Feb;40(2):157-63.

PMID:
15770399
4.

Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.

Hazzan R, Tur-Kaspa R.

J Clin Gastroenterol. 2010 May-Jun;44(5):371-3. doi: 10.1097/MCG.0b013e3181c115b3.

PMID:
19881358
5.

Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation.

Hidaka M, Iwasaki S, Matsui T, Kawakita T, Inoue Y, Sakai T, Harada N, Takemoto S, Nagakura S, Kiyokawa T, Takahashi M, Saibara T, Onishi S, Kawano F.

Bone Marrow Transplant. 2010 May;45(5):912-8. doi: 10.1038/bmt.2009.251. Epub 2009 Oct 5.

PMID:
19802024
6.

A novel treatment for refractory primary biliary cirrhosis?

Miyaguchi S, Ebinuma H, Imaeda H, Nitta Y, Watanabe T, Saito H, Ishii H.

Hepatogastroenterology. 2000 Nov-Dec;47(36):1518-21.

PMID:
11148991
7.

Increased intercellular adhesion molecule-1 serum concentration in cholestasis.

Polzien F, Ramadori G.

J Hepatol. 1996 Dec;25(6):877-86.

PMID:
9007716
8.

Bezafibrate treatment: a new medical approach for PBC patients?

Kanda T, Yokosuka O, Imazeki F, Saisho H.

J Gastroenterol. 2003;38(6):573-8.

PMID:
12825134
9.

Bezafibrate for the treatment of primary sclerosing cholangitis.

Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, Kawakubo K, Ito Y, Kogure H, Sasaki T, Arizumi T, Togawa O, Matsubara S, Nakai Y, Sasahira N, Tsujino T, Isayama H, Kawabe T, Omata M, Koike K.

J Gastroenterol. 2010 Jul;45(7):758-62. doi: 10.1007/s00535-010-0204-x. Epub 2010 Feb 3.

PMID:
20127368
10.

Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.

Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, Denk H, Zatloukal K, Trauner M.

Hepatology. 2001 Mar;33(3):633-46.

PMID:
11230744
11.

Elevated level of serum Mn-superoxide dismutase in patients with primary biliary cirrhosis: possible involvement of free radicals in the pathogenesis in primary biliary cirrhosis.

Ono M, Sekiya C, Ohhira M, Ohhira M, Namiki M, Endo Y, Suzuki K, Matsuda Y, Taniguchi N.

J Lab Clin Med. 1991 Nov;118(5):476-83.

PMID:
1682406
12.

Effect of bezafibrate in primary biliary cirrhosis: a pilot study.

Ohmoto K, Mitsui Y, Yamamoto S.

Liver. 2001 Jun;21(3):223-4. No abstract available.

PMID:
11422787
13.

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.

Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, Saito Y, Takikawa H, Imawari M, Matsuzaki Y.

Hepatology. 2013 May;57(5):1931-41. doi: 10.1002/hep.26018. Epub 2013 Apr 5.

PMID:
22911624
14.

Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4.

Shoda J, Inada Y, Tsuji A, Kusama H, Ueda T, Ikegami T, Suzuki H, Sugiyama Y, Cohen DE, Tanaka N.

J Lipid Res. 2004 Oct;45(10):1813-25. Epub 2004 Jul 16.

15.

Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.

Dohmen K, Tanaka H, Haruno M.

Fukuoka Igaku Zasshi. 2013 Oct;104(10):350-61.

PMID:
24511666
16.

Biliary indocyanine green excretion as a predictor of hepatic adenosine triphosphate levels in patients with obstructive jaundice.

Chijiiwa K, Watanabe M, Nakano K, Noshiro H, Tanaka M.

Am J Surg. 2000 Feb;179(2):161-6.

PMID:
10773154
19.

Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.

Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M.

J Hepatol. 2003 Jun;38(6):717-27.

PMID:
12763363
20.

Hepatocyte ultrastructural aspects after preoperative biliary drainage in pancreatic cancer patients with cholestatic jaundice.

Fiori E, Macchiarelli G, Schillaci A, Lamazza A, Burza A, Paparelli C, Cavallaro A, Cangemi V.

Anticancer Res. 2003 Nov-Dec;23(6C):4859-63.

PMID:
14981936

Supplemental Content

Support Center